Published in J Thorac Oncol on August 01, 2009
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis (2013) 1.27
Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis (2013) 0.91
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg (2012) 0.90
The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol (2011) 0.88
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br J Cancer (2013) 0.86
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position. Thorax (2013) 0.82
CD74: a new prognostic factor for patients with malignant pleural mesothelioma. Br J Cancer (2014) 0.81
Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery. Ann Cardiothorac Surg (2012) 0.77
An exception that proves the rule: recurrence free survival five years after extrapleural pneumonectomy for malignant pleural mesothelioma. J Cardiothorac Surg (2014) 0.75
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A (2002) 2.32
Catheter tract metastasis associated with indwelling pleural catheters. Chest (2014) 2.18
Five year clinical follow up of patients who have had off pump coronary artery bypass grafting. Heart Lung Circ (2003) 2.04
Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys (2012) 1.85
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75
Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol (2007) 1.74
Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol (2010) 1.73
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol (2013) 1.59
Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? Eur J Cancer (2010) 1.55
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol (2012) 1.51
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. Asia Pac J Clin Oncol (2010) 1.40
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol (2011) 1.29
Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys (2002) 1.25
Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res (2010) 1.25
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One (2009) 1.24
Circulating miRNA biomarkers for Alzheimer's disease. PLoS One (2013) 1.22
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med (2007) 1.19
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother (2008) 1.18
Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest (2012) 1.18
Inflammation modulates human HDL composition and function in vivo. Atherosclerosis (2012) 1.18
Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology (2003) 1.16
A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report. J Med Case Rep (2013) 1.12
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology (2013) 1.11
A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer (2004) 1.09
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One (2013) 1.08
Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology (2012) 1.07
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol (2013) 1.03
Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial. BMC Cancer (2011) 1.03
Prospective analysis of fluoroscopy duration during ERCP: critical determinants. Gastrointest Endosc (2010) 1.03
The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol (2012) 1.01
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer (2013) 1.00
Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol (2011) 0.98
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res (2014) 0.97
A randomized controlled trial of the computerized CBT programme, MoodGYM, for public mental health service users waiting for interventions. Br J Clin Psychol (2014) 0.97
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis (2007) 0.96
Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet (2004) 0.95
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer (2009) 0.94
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs (2006) 0.94
The information and support needs of patients diagnosed with High Grade Glioma. Patient Educ Couns (2009) 0.93
Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk? Radiat Oncol (2014) 0.92
Catastrophic presentation of atrial myxoma with total occlusion of abdominal aorta. Interact Cardiovasc Thorac Surg (2009) 0.92
Topographic association of gastric epithelial expression of Ki-67, Bax, and Bcl-2 with antralization in the gastric incisura, body, and fundus. Am J Gastroenterol (2002) 0.92
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology (2010) 0.91
Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system. Radiother Oncol (2008) 0.91
First-line treatment of deep sternal infection by a plastic surgical approach: superior results compared with conventional cardiac surgical orthodoxy. Plast Reconstr Surg (2002) 0.91
PKR regulates proliferation, differentiation, and survival of murine hematopoietic stem/progenitor cells. Blood (2013) 0.90
Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res (2013) 0.90
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol (2012) 0.89
Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med (2012) 0.88
Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile? Lung Cancer (2011) 0.87
Endoscopic management of gastric variceal bleeding with cyanoacrylate glue injection: safety and efficacy in a Canadian population. Can J Gastroenterol (2010) 0.87
Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunol Immunother (2012) 0.87
Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study. Melanoma Res (2004) 0.87
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid (2015) 0.86
The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. J Clin Oncol (2013) 0.86
Current state and future directions of pleural mesothelioma imaging. Lung Cancer (2007) 0.85
Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol (2014) 0.85
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci (2011) 0.85
A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer (2005) 0.84
Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol (2012) 0.84
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol (2007) 0.83
Prospective trial of intraoperative radiation treatment for breast cancer. ANZ J Surg (2004) 0.83
A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible. Int J Radiat Oncol Biol Phys (2009) 0.83
Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg (2009) 0.83
Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer (2014) 0.82
Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci (2012) 0.81
Atrial myxoma with coexistent coronary artery disease: a report of two cases. Heart Lung Circ (2003) 0.81
Small cell lung cancer presenting with paraneoplastic limbic encephalitis. Asia Pac J Clin Oncol (2011) 0.81
Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother (2012) 0.81
MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma. Eur J Cancer (2010) 0.81
Antralization of gastric incisura is topographically associated with increased gastric epithelial apoptosis and proliferation, but not with CagA seropositivity. J Gastroenterol Hepatol (2004) 0.80
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol (2013) 0.80
The antioxidants vitamins A and E and selenium do not reduce the incidence of asbestos-induced disease in a mouse model of mesothelioma. Nutr Cancer (2012) 0.80
Retrospective analysis of radiation exposure during endoscopic retrograde cholagiopancreatography: critical determinants. Can J Gastroenterol (2011) 0.79
Novel targeted therapies and vaccination strategies for mesothelioma. Curr Treat Options Oncol (2011) 0.79
Chest pain? Cause. Lancet (2004) 0.79
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol (2013) 0.78
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. Support Care Cancer (2007) 0.78
Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? Lung Cancer (2013) 0.78
Insulin-like growth factor I receptor β expression in hepatocellular carcinoma. Hum Pathol (2011) 0.78
Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? Future Oncol (2014) 0.78
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer (2008) 0.78
Use of an occlusive dressing for 2 weeks reduces the incidence of sternal wound infections. ANZ J Surg (2005) 0.78
Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions. J Thorac Oncol (2014) 0.78
Radiotherapy in the management of high-grade gliomas diagnosed in Western Australia: a patterns of care study. J Med Imaging Radiat Oncol (2012) 0.78